BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 33931473)

  • 21. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
    Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
    Gatto L; Franceschi E; Nunno VD; Brandes AA
    Immunotherapy; 2020 Oct; 12(15):1111-1114. PubMed ID: 32594820
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
    Abdayem P; Planchard D
    Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N; Tirpack A; Chan KK; Bass AR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

  • 27. Recent advances in vaccine and immunotherapy for COVID-19.
    Rabaan AA; Al-Ahmed SH; Sah R; Al-Tawfiq JA; Al-Qaaneh AM; Al-Jamea LH; Woodman A; Al-Qahtani M; Haque S; Harapan H; Bonilla-Aldana DK; Kumar P; Dhama K; Rodriguez-Morales AJ
    Hum Vaccin Immunother; 2020 Dec; 16(12):3011-3022. PubMed ID: 33156739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
    Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Messenger RNA vaccines against SARS-CoV-2.
    Topol EJ
    Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition.
    de Joode K; Oostvogels AAM; GeurtsvanKessel CH; de Vries RD; Mathijssen RHJ; Debets R; van der Veldt AAM
    Front Immunol; 2021; 12():627186. PubMed ID: 33613575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
    Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
    Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune Checkpoint Inhibitor Pneumonitis, From the
    Nishino M
    AJR Am J Roentgenol; 2022 Jan; 218(1):19-27. PubMed ID: 33594904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Open Letter: COVID-19 and Cancer.
    Printz C
    Cancer; 2021 Apr; 127(8):1171. PubMed ID: 33878202
    [No Abstract]   [Full Text] [Related]  

  • 34. T Cell Memory: Understanding COVID-19.
    Jarjour NN; Masopust D; Jameson SC
    Immunity; 2021 Jan; 54(1):14-18. PubMed ID: 33406391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature.
    Dai Y; Liu S; Zhang Y; Li X; Zhao Z; Liu P; Du Y
    J Med Case Rep; 2021 Feb; 15(1):41. PubMed ID: 33522942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.
    Pala L; Conforti F; Cocorocchio E; Ferrucci P; De Pas MT; Stucchi S; Repetto M; Saponara M; Queirolo P
    Cancer Invest; 2021 Jan; 39(1):9-14. PubMed ID: 33125301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
    Lasagna A; Lenti MV; Cassaniti I; Sacchi P
    Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mRNA vaccine for cancer immunotherapy.
    Miao L; Zhang Y; Huang L
    Mol Cancer; 2021 Feb; 20(1):41. PubMed ID: 33632261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
    Isgrò MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA
    J Transl Med; 2021 Mar; 19(1):132. PubMed ID: 33789686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.